Investor Relations

Advanced therapies for the sports medicine and severe burn care markets

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 41 st Annual J.P. Morgan Healthcare Conference.
View HTML
Toggle Summary Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 42 nd Annual J.P. Morgan Healthcare Conference.
View HTML
Toggle Summary Vericel to Present at the 5th Annual Cell & Gene Therapy Investor Day
CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the 5th
View HTML
Toggle Summary Vericel to Present at the 6th Annual Cell & Gene Therapy Investor Day
CAMBRIDGE, Mass. , April 10, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 6 th Annual
View HTML
Toggle Summary Vericel to Present at the 7th Annual Leerink Partners Global Healthcare Conference
CAMBRIDGE, Mass. , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 7 th Annual
View HTML
Toggle Summary Vericel to Present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020
CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 9 th Annual SVB Leerink
View HTML
Toggle Summary Vericel to Present at the BIO CEO & Investor Conference
CAMBRIDGE, Mass. , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the BIO CEO &
View HTML
Toggle Summary Vericel to Present at the Canaccord Genuity Medical Technologies & Diagnostic Forum
CAMBRIDGE, Mass. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the Canaccord
View HTML
Toggle Summary Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Musculoskeletal Conference in
View HTML
Toggle Summary Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference.
View HTML

Day High:
Day Low:
Volume:
on
Data Provided by Refinitiv. Minimum 15 minutes delayed.